SCHEMBL10310271

SCHEMBL10310271

N=C(N)Nc1cccc2nonc12

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.51
MEN1 O00255 5/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MAPK1 P28482 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
ALDH1A1 P00352 5/20 0.42
MAPT P10636 3/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
POLB P06746 3/20 0.40
RXFP1 Q9HBX9 1/20 0.40
GFER P55789 1/20 0.40
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
FPR3 P25089 1/20 0.35
FPR2 P25090 1/20 0.35
FAAH O00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29386170 0.77 KMT2A (0.59) KMT2AMEN1L3MBTL1MAPK1TDP1
SCHEMBL61006 0.73 KMT2A (0.64) KMT2AMEN1L3MBTL1MAPK1TDP1
Hydrochloric Acid SCHEMBL29845935 0.72 KMT2A (0.39) KMT2AMEN1L3MBTL1MAPK1TDP1
SCHEMBL896641 0.70 KMT2A (0.48) KMT2AMEN1L3MBTL1MAPK1TDP1
SCHEMBL11067308 0.69 KMT2A (0.54) KMT2AMEN1L3MBTL1MAPK1TDP1
SCHEMBL16004866 0.69 KMT2A (0.68) KMT2AMEN1L3MBTL1MAPK1TDP1
SCHEMBL2002382 0.69 GAA (0.50) KMT2AL3MBTL1MAPK1ALDH1A1MAPT
SCHEMBL19472798 0.68 RAB9A (0.55) KMT2AMEN1MAPK1ALDH1A1MAPT
SCHEMBL7439111 0.68 KDM4E (0.41) KMT2AMEN1L3MBTL1MAPK1ALDH1A1
SCHEMBL61427 0.68 MAPT (0.48) KMT2AMEN1L3MBTL1MAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799684-B1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARM INC (US) 2014-12-03 EP disclosed
US-20120178739-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-07-12 US disclosed
US-20120178739-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-07-12 US disclosed
US-20110039820-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 US disclosed
US-20110039820-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 US disclosed
US-20090105213-A1 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-23 US disclosed
US-20090105213-A1 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-23 US disclosed
US-7459448-B2 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-7459448-B2 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178739-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS PRKCI, PIK3CA, AKT1 KMT2A 2007/4885MEN1 1532/4885L3MBTL1 4000/4885
US-20090105213-A1 Lactam compounds useful as protein kinase inhibitors PRKCI, PIK3CA, AKT1 KMT2A 2007/4885MEN1 1532/4885L3MBTL1 4000/4885
US-20110039820-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS PRKCI, PIK3CA, AKT1 KMT2A 2007/4885MEN1 1532/4885L3MBTL1 4000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.